Emerging investigations on retatrutide, a dual stimulant for incretin hormone and GIP, demonstrate encouraging findings in addressing weight gain and type 2 glucose intolerance. Initial data from clinical experiments reveal notable decreases in body weight and bettered glucose levels. Further res